GlassScriptPhysician profile
Katie King
NPI 1790137669
$4,475.36
in general payments reported to CMS, 2019-2025
32 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $1,724 · 2023: $1,849 · 2024: $98.53 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $966.01 | 2021-2025 | Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Abbvie INC. | $928.50 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $466.28 | 2022-2025 | Xtampza, Belbuca |
| Vertos Medical, INC. | $274.87 | 2021-2023 | Mild Device Kit |
| Grt US Holding, INC. | $154.41 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $147.11 | 2022-2023 | Ztlido |
| Pfizer INC. | $143.21 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.74 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.09 | 2022-2023 | Trintellix |
| Lilly USA, LLC | $109.80 | 2022-2023 | Reyvow, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.59 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $102.91 | 2022-2023 | Belsomra |
| Averitas Pharma INC. | $99.84 | 2023 | Qutenza |
| Amgen INC. | $86.43 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $74.70 | 2022-2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $71.07 | 2021-2022 | |
| Ibsa Pharma INC. | $70.36 | 2022-2023 | Tirosint, Licart |
| Supernus Pharmaceuticals, INC. | $55.61 | 2022 | |
| Tersera Therapeutics LLC | $49.33 | 2021-2022 | |
| Axsome Therapeutics, INC. | $42.90 | 2023 | Auvelity |
| Abbott Laboratories | $42.29 | 2021 | |
| Almatica Pharma LLC | $41.76 | 2023 | Gralise |
| Lundbeck LLC | $28.84 | 2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $28.46 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $23.41 | 2025 | |
| Redhill Biopharma INC. | $19.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.16 | 2022 | |
| Novo Nordisk INC | $18.06 | 2023 | Ozempic, Rybelsus |
| Relievant Medsystems, INC. | $17.15 | 2021 | |
| Valinor Pharma, LLC | $14.16 | 2025 | Movantik |
| Azurity Pharmaceuticals, INC. | $11.71 | 2022 | |
| Medtronic, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.